Effects of Induction Chemotherapy of Docetaxel, Cisplatin, and5-Fluorouracil Combining Intensity-Modulated Radiotherapy andConcurrent Chemotherapy in Locoregionally Advanced NasopharyngealCarcinoma

F. He, Yan Ma, Jian Zheng, X. Pang, Qun Zhang, Wei Luo, X. Wan
{"title":"Effects of Induction Chemotherapy of Docetaxel, Cisplatin, and5-Fluorouracil Combining Intensity-Modulated Radiotherapy andConcurrent Chemotherapy in Locoregionally Advanced NasopharyngealCarcinoma","authors":"F. He, Yan Ma, Jian Zheng, X. Pang, Qun Zhang, Wei Luo, X. Wan","doi":"10.4172/2329-6771.1000147","DOIUrl":null,"url":null,"abstract":"Purpose: Nasopharyngeal carcinoma (NPC) has the worldwide highest incidence in Southern China. Here, we investigate the efficacy and safety of induction chemotherapy of docetaxel, cisplatin, and 5-fluorouracil (TPF) plus concurrent cisplatin based intensity-modulated radiotherapy (IMRT) in locoregionally advanced NPC. \nMaterials and Methods: From October 2009 to August 2012, 76 NPC patients treated by TFP induction chemotherapy plus concurrent cisplatin-IMRT were retrospectively recruited. The survival rate, accurate and late toxicities were further analyzed with 3 year follow-up. \nResults: The median follow-up time was 42 months (range, 8 to 60 months). The 3- year disease free survival (DFS), overall survival (OS), Local relapse free survival (LRFS), Distant metastasis free survival (DMFS) was 86.6%, 94.5%, 94.7%, and 89.2%, respectively. The major acute toxicities were myelosuppression, gastrointestinal disorders, and mucositis. The major late toxicities were skin reaction, xerostomia and hearing loss. Multivariate analyses indicated that lymph node metastasis status (N stage) was independent prognostic factor for DFS (P = 0.044, hazard ratio 4.832) and DMFS (P = 0.036, hazard ratio 7.309). \nConclusions: TPF induction chemotherapy plus concurrent cisplatin-IMRT achieved satisfying 3-year survival rates with acceptable toxicities, suggesting that this combined therapeutic regimen might be effective for locoregionally advanced NPC.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"2 1","pages":"1-6"},"PeriodicalIF":0.0000,"publicationDate":"2015-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Integrative Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2329-6771.1000147","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Purpose: Nasopharyngeal carcinoma (NPC) has the worldwide highest incidence in Southern China. Here, we investigate the efficacy and safety of induction chemotherapy of docetaxel, cisplatin, and 5-fluorouracil (TPF) plus concurrent cisplatin based intensity-modulated radiotherapy (IMRT) in locoregionally advanced NPC. Materials and Methods: From October 2009 to August 2012, 76 NPC patients treated by TFP induction chemotherapy plus concurrent cisplatin-IMRT were retrospectively recruited. The survival rate, accurate and late toxicities were further analyzed with 3 year follow-up. Results: The median follow-up time was 42 months (range, 8 to 60 months). The 3- year disease free survival (DFS), overall survival (OS), Local relapse free survival (LRFS), Distant metastasis free survival (DMFS) was 86.6%, 94.5%, 94.7%, and 89.2%, respectively. The major acute toxicities were myelosuppression, gastrointestinal disorders, and mucositis. The major late toxicities were skin reaction, xerostomia and hearing loss. Multivariate analyses indicated that lymph node metastasis status (N stage) was independent prognostic factor for DFS (P = 0.044, hazard ratio 4.832) and DMFS (P = 0.036, hazard ratio 7.309). Conclusions: TPF induction chemotherapy plus concurrent cisplatin-IMRT achieved satisfying 3-year survival rates with acceptable toxicities, suggesting that this combined therapeutic regimen might be effective for locoregionally advanced NPC.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
多西紫杉醇、顺铂、5-氟尿嘧啶诱导化疗联合调强放疗及同期化疗治疗局部晚期鼻咽癌的疗效观察
目的:鼻咽癌(NPC)是世界上发病率最高的地区之一。在这里,我们研究了多西紫杉醇、顺铂和5-氟尿嘧啶(TPF)诱导化疗联合顺铂调强放疗(IMRT)治疗局部进展期鼻咽癌的疗效和安全性。材料与方法:回顾性收集2009年10月至2012年8月期间接受TFP诱导化疗联合顺铂- imrt治疗的鼻咽癌患者76例。随访3年,进一步分析生存率、准确率和晚期毒性。结果:中位随访时间为42个月(8 ~ 60个月)。3年无病生存期(DFS)、总生存期(OS)、局部无复发生存期(LRFS)、无远处转移生存期(DMFS)分别为86.6%、94.5%、94.7%和89.2%。主要的急性毒性是骨髓抑制、胃肠道紊乱和粘膜炎。晚期毒性主要为皮肤反应、口干和听力丧失。多因素分析显示,淋巴结转移状态(N分期)是DFS (P = 0.044,风险比4.832)和DMFS (P = 0.036,风险比7.309)的独立预后因素。结论:TPF诱导化疗联合顺铂- imrt获得了令人满意的3年生存率和可接受的毒性,表明这种联合治疗方案可能对局部区域晚期鼻咽癌有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Time-restricted Eating to Address Cancer-related Fatigue among Cancer Survivors: A Single-arm Pilot Study. PROGNOSTIC IMPORTANCE OF MOLECULAR GENETIC MARKERS: Ki67, Bcl2, and p53 IN PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER Role of Vitronectin as a potential Serum Biomarker for Breast Cancer Prognosis Botulinum Toxin Usefulness in the Treatment of Drooling in Childhood Breast cancer risk factors, prevention and patients empowerment
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1